STOCKS TELEGRAPH

Tag: PALI STOCK

  • Decoding The Surge: Palisade Bio (PALI) Shares On The Move

    Decoding The Surge: Palisade Bio (PALI) Shares On The Move

    The current trading session has witnessed a notable surge in the shares of Palisade Bio, Inc. (NASDAQ: PALI), with an impressive increase of 21.46%, elevating its value to $7.32. This substantial uptick in PALI stock price follows the successful completion of an analysis for the development of a new drug.

    Today, Palisade Bio (PALI) has announced the successful conclusion of its analysis assessing the impact of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay. PALI-2108, an orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug developed by Palisade, targets patients afflicted with UC.

    The obtained data fortifies Palisade Bio’s confidence in the robust anti-inflammatory capabilities of PALI-2108 in managing UC. The superior efficacy of PALI-2108, evidenced by its lower half-maximal inhibitory concentration (IC50) compared to the approved PDE4 inhibitor apremilast, underscores its potential as an advanced therapeutic option for inflammatory bowel disease patients.

    This comprehensive study involved WB samples from 14 clinically healthy adults, comprising five women and nine men. Twelve samples meeting the inclusion criteria were utilized for TNF-α measurement and IC50 value calculation. Donor whole blood underwent treatment with varied concentrations of PALI-2108 and two control compounds known for inhibiting the PDE4 pro-inflammatory pathway, subsequently being challenged with the pro-inflammatory molecule lipopolysaccharide (LPS).

    Anti-inflammatory potency was determined by computing IC50 values for TNF-α inhibition. Results from the study showcased the efficacy of PALI-2108 in inhibiting LPS-induced TNF-α production in this ex-vivo peripheral whole blood assay. Pretreatment of human whole blood samples with bioactivated PALI-2108 led to a significant reduction in LPS-induced TNF-α production compared to non-pretreated samples.

    The study was conducted in collaboration with Paraza Pharma, Inc., headquartered in Montreal, QC. Palisade Bio’s exceptional operational performance is propelling the clinical advancement of PALI-2108 towards its first-in-human study, slated to commence later this year. Palisade Bio remains dedicated to advancing its innovative research endeavors aimed at enhancing the quality of life for UC patients and those affected by other inflammatory conditions.

  • Palisade Bio (PALI) Stock Momentum: Clinical Trial Findings Fuel Surge

    Palisade Bio (PALI) Stock Momentum: Clinical Trial Findings Fuel Surge

    Following the release of promising clinical trial data, the shares of Palisade Bio, Inc. (NASDAQ: PALI) are experiencing a notable surge on the US stock charts. As of the last check during current session, PALI stock recorded a remarkable uptick of 105.77%, reaching $8.56.

    Palisade Bio (PALI) has disclosed today the successful culmination of its scrutiny evaluating ex-vivo bioactivation of PALI-2108. PALI-2108 is an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in the developmental phase, targeting patients afflicted by UC.

    The findings have unveiled that PALI-2108 showcases proficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples, sourced from both healthy volunteers and UC patients. The enzymatic activity in stool samples was gauged through LC-MS analysis, with all samples meeting the target conversion rate within a 24-hour timeframe.

    The evaluation has revealed that PALI-2108 was transmutated into its active PDE4 inhibitor form at an average rate of 90.1%, with conversion exhibiting a consistent upward trend over time. This study was conducted in collaboration with Altasciences, headquartered in Montreal, QC. These results fortify Palisade Bio’s confidence in PALI-2108 as a precisely targeted therapy for moderate-to-severe UC.

    The successful bioactivation of PALI-2108 into its active PDE4 inhibitor form, maintaining consistently high conversion rates over a 24-hour duration in stool samples, accentuates its potential as an innovative therapeutic intervention for managing UC. Palisade Bio recently participated in IBD Innovate: Product Development for Crohn’s & Colitis, held on April 9-10, 2024, in Cambridge, MA.

    As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research collaborator, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio, delivered an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” elucidating on the development of PALI-2108, its distinctive features, competitive positioning, and the clinical trajectory toward late-stage development.

    As previously disclosed, the progression of PALI-2108 is backed by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.

  • Palisade Bio Inc. (PALI) Stock Climbing with the Pump

    Palisade Bio Inc. (NASDAQ: PALI) is a pharmaceutical company that holds specialized expertise in the domain of the mucus barrier protecting the gastrointestinal tract. With this set of specialized skills, the company holds immense potential for seeing its pipeline develop into an enhanced product line. Its stock has been spontaneously surging as of late.

    PALI Undertakes Impressive Climb

    PALI stock has had a couple of field days, taking on an impressive bullish climb, with no real fundamental or business-related updates coming from management. In just the last three days, the stock price saw a remarkable takeoff, which brought it from $1.80 to $3.39. This 80% rise seemingly comes from a coordinated attempt at what apparently is a pump, which makes it unpredictable to spot an entry point for retail traders.

    A Broader Look into Palisade Bio Inc.

    Despite PALI stock’s takeoff being described as an artificial pump by a certain segment of market participants, it remains difficult to overlook the strengths it inherently holds. As a pharmaceutical company, Palisade Bio saw the achievement of several milestones throughout 2022. Most recently, its LB1148 trial candidate saw a granting of fast-track designation by the US FDA. This drug is highly effective in treating impacted bowel function following surgeries of a gastrointestinal nature. Fast-tracking any candidate is always major news, as it significantly accelerates the development process, and brings its commercialization much sooner than the standard channels. The company, therefore, has a strong overall pipeline of treatments that are each highly capable of hitting the shelves with a sound development process, overall.

    Conclusion

    PALI stock pushes on with its mighty climb in what appears to be a coordinated attempt at a price pump. However, the strong promise that the biotech company holds may suggest that the dump may not be as severe as bears would expect.

  • Palisade Bio Inc. (PALI) stock on a Downward Spiral Following its Fiscal 2021 Results

    On March 18, Palisade Bio Inc. (PALI) reported its financial and operations results for fiscal 2021. Consequently, the stock entered a downward spiral in regular trading which continued into the after-hours with a further loss.

    PALI suffered a loss of 11.56% during the regular session after fluctuating between $0.88 and $0.98. At the close of the session, the stock had a value of $0.88 per share while the volume was 1.71 million shares. Valuing at $0.76 in the after-hours, the stock lost 13.64% against its previously closed price. Thus, PALI declined by a further $0.12 in the after-hours while the number of shares traded was 347.56K.

    The biopharmaceutical company, Palisade Bio Inc. is based in Carlsbad, CA. With a current market capitalization of $11.95 million, the company has 13.57 million outstanding shares. In the past five days, PALI has lost 15.38%, while losing 32.31% year to date. Moreover, the stock subtracted a huge value of 91.06% in the past year.

    Source: Insurance Info Institute

    PALI’s Fiscal 2021 Summary

    In fiscal 2021, the company’s R&D expenses declined to $2.4 million against $3.1 million in the previous year. The cause of this decline was the decrease in clinical trial activities due to the pandemic.

    Furthermore, the company saw an increase in G&A expenses due to higher professional fees emerging from its title as a public company. The G&A expenses were $9.3 million in fiscal 2021, against $6.2 million in 2020.

    PALI ended the year with cash and cash equivalents of $10.5 million and outstanding debt of less than $0.1 million. Additionally, the cash used in operations during the year was $14.8 million.

    Milestones for 2022

    The company intends to focus on the clinical advancement of its LB1148, a broad-spectrum serine protease inhibitor. The phase 3 study is expected to commence in the first half of 2022 with patient enrolment in the second half. Also, patient enrolment for phase 2 study under an amended protocol is expected in H1 2022.

    PALI’s Other Developments

    On March 16, the company announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN. The major highlights of the data were: 72% of reduction in adhesions incidence due to LB1148 in patients undergoing bowel resection; and 93% reduction in extent and severity of adhesions.

    The data was featured at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting.